Edesa Biotech Announces Registered Offering to Raise ~ $23.1M

What Happened

• Edesa Biotech, Inc. (EDSA) announced on August 19, 2026 that it entered into an underwriting agreement with Guggenheim Securities for an underwritten registered offering expected to close on or about August 21, 2026. The deal includes common shares, pre-funded warrants and accompanying common share warrants. The company expects net proceeds of approximately $23.1 million after fees and expenses. Proceeds are intended for general corporate purposes, including working capital, capital expenditures and R&D/manufacturing expenses.

Key Details

• Offering structure:
  • 3,870,500 common shares with accompanying common share warrants at a combined price of $5.50 per share + warrant.
  • Pre-funded warrants to purchase up to 675,000 common shares with accompanying common share warrants at a combined price of $5.4999 (pre-funded warrant exercise price $0.0001).
  • Underwriters have a 30-day option to buy up to 681,825 additional common shares and accompanying warrants on the same terms.
• Warrant terms:
  • Common share warrants: exercisable for one common share at $7.50 per share; exercisable until the earlier of 18 months after issuance or 30 days after the Company’s public announcement of Phase 2 vitiligo topline data for EB06.
  • Pre-funded warrants: exercisable immediately, initial exercise price $0.0001, no termination date.
  • Beneficial ownership limits: holders may not exercise to exceed 4.99% ownership (or 9.99% if elected prior to issuance); holders can change that limit with 61 days’ notice.
• Other material items: 90-day lock-up restrictions on the company and, subject to exceptions, on executive officers and directors; offering made under a Form S-3 registration statement (File No. 333-288966) effective Sept 9, 2025. Press releases announcing the launch and pricing were issued Aug 19, 2026.

Why It Matters

• This transaction is a material capital raise for Edesa and provides near-term funding (about $23.1M net) to support operations and development. For investors, the offering means immediate potential dilution if all shares and associated warrants are issued and additional dilution if warrants and pre-funded warrants are exercised. The warrant terms (including exercise price, expiration triggers and ownership caps) affect the timing and degree of future dilution. The 90-day lock-up temporarily limits insider sales following the offering. The offering is subject to customary closing conditions and therefore is not guaranteed until closing.